Mesoblast (ASX: MSB) is an Australian-listed company in the Healthcare sector with a market capitalisation of $2.75B and the 183rd-largest security on the ASX by market capitalisation. The MSB share price is $2.13, up 3.40% today and up 27.54% over the past 12 months. Shares have traded between $1.5275 and $3.31 over the past 52 weeks. In its most recent reported period (ending 30 June 2025), Mesoblast reported revenue of $7.0M and a net loss of $27.1M.
About Mesoblast Limited
Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerland. Its therapeutic endeavors encompass a wide array of medical conditions, including cardiovascular diseases, spinal and orthopedic ailments, oncology, hematology, and immune-mediated and inflammatory disorders. Mesoblast's distinctive regenerative medicine platform is founded on the therapeutic potential of specialized mesenchymal lineage cells. A prominent candidate, Remestemcel-L, is currently in late-stage (Phase III) clinical trials for various systemic inflammatory conditions, such as steroid-refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic-refractory inflammatory bowel disease. Additionally, Remestemcel-L is undergoing Phase III evaluation for chronic heart failure and chronic low back pain linked to degenerative disc disease. The company's pipeline also features MPC-300-IV, under development for biologic-refractory rheumatoid arthritis and diabetic nephropathy, and MPC-25-IC, aimed at treating or preventing acute myocardial infarction. Mesoblast has forged key strategic partnerships, including one with Tasly Pharmaceutical Group for the commercialization of MPC-150-IM (for heart failure) and MPC-25-IC (for heart attacks) in China. It also collaborates with JCR Pharmaceuticals Co. Ltd. on wound healing therapies for epidermolysis bullosa patients, and with Grünenthal to advance and market a cell therapy for chronic low back pain.
SNZ
NEU
PYC
CU6
SPL
DXB
ILA
IMM
